Here's Why Revance Therapeutics (RVNC) Outperformed in Q1
Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Revance Therapeutics Inc. (RVNC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Palo Alto Investors William Leland Edwards | 5,270,209 | $169,753,432 | -1% | 14.06% |
| 2. | Polar Capital Brian Ashford-Russell And Tim Woolley | 4,167,842 | $134,246,191 | -15% | 0.97% |
| 3. | D E Shaw D. E. Shaw | 2,291,911 | $73,822,453 | +72% | 0.07% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 1,549,500 | $49,909,395 | +33% | 0.12% |
| 5. | Jericho Capital Asset Management Josh Resnick | 1,438,669 | $46,339,528 | +54% | 1.92% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.74 | 6,400 | Director | 26,913 | 2021-12-13 | Filing | |
| $14.43 | 30,000 | Officer, Director | 95,463 | 2021-12-03 | Filing | |
| $12.90 | 40,000 | Officer, Director | 110,913 | 2021-11-29 | Filing | |
| $31.20 | 900 | Director | 6,150 | 2018-03-16 | Filing | |
| $31.25 | 2,250 | Director | 5,250 | 2018-03-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.00 | 500 | Officer | 80,828 | 2023-06-02 | Filing | |
| $30.57 | 2,701 | Officer | 81,328 | 2023-06-01 | Filing | |
| $34.55 | 21,401 | Officer | 69,165 | 2023-05-15 | Filing | |
| $34.55 | 21,401 | Officer | 84,029 | 2023-05-15 | Filing | |
| $34.55 | 70,447 | Officer, Director | 923,212 | 2023-05-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 10,076,101 | $324,551,213 | 0.06% | |
| 2. | 6,139,064 | $197,739,254 | 0% | |
| 3. | 5,164,157 | $166,338,000 | 0.1% | |
| 4. | 4,599,745 | $148,157,786 | 0% | |
| 5. | 2,274,491 | $73,261,357 | 0.03% |
News See All
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2023 Earnings Call Transcript
Operator: Welcome to the Revance Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2022 Earnings Call Transcript
Operator: Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Reasons for the Decline of Revance Therapeutics (RVNC) in Q4
Baron Funds, an investment management company, released its “Baron Discovery Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2022 Earnings Call Transcript
Operator: Welcome to the Revance Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Here's What Makes Revance Therapeutics (RVNC) an Attractive Investment
Baron Funds, an investment management company, released its “Baron Discovery Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here.
Is Revance Therapeutics (RVNC) a Worthy Investment Pick?
Baron Funds, an asset management firm, published its “Baron Discovery Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
Should You Remain Optimistic in Your Revance Therapeutics (RVNC) Position?
Baron Funds, an asset management firm, published its “Baron Discovery Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors
In this article, we will take a look at 15 biotech and pharmaceutical stocks to buy according to Palo Alto Investors.
Billionaire Hedge Funds
